Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ISA 2020 | Kidney transplantation in AL amyloidosis & monoclonal immunoglobulin deposition disease

Nelson Leung • 2 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Nelson Leung, MD, Mayo Clinic, Rochester, MN, discusses kidney transplantation in immunoglobulin light chain (AL) amyloidosis and monoclonal immunoglobulin deposition disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Nelson Leung

Current approaches to treating and managing MGUS
0:59
Current approaches to treating and managing MGUS
Nelson Leung • 28 Sep 2023
Diagnosis and potential therapeutic options for AA amyloidosis
1:51
Diagnosis and potential therapeutic options for AA amyloidosis
Nelson Leung • 28 Sep 2023
Addressing nephrotoxicity in agents commonly used to treat multiple myeloma
1:22
Addressing nephrotoxicity in agents commonly used to treat multiple myeloma
Nelson Leung • 28 Sep 2023
Understanding the concept of MGRS
0:58
Understanding the concept of MGRS
Nelson Leung • 28 Sep 2023

Related Videos

Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Nelson Leung • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Nelson Leung • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Nelson Leung • 8 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Nelson Leung • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals